A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE) (Novartis CABL01AUS08) (NCT05384587)
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
Principal Investigator(s)
Kelsey Sokol
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695
Stamford, CT 06902
Main: 203-276-2695